Evidence of a Sjögren's disease-like phenotype following COVID-19 in mice and humans
Sjögren's Disease (SjD) is a systemic autoimmune disease characterized by lymphocytic inflammation of the lacrimal and salivary glands (SG), dry eyes and mouth, and systemic symptoms. SARS-CoV-2 may trigger the development or progression of autoimmune diseases. To test this, we used a mouse model of SARS-CoV-2 infection and convalescent patients' blood and SG in order to understand the development of SjD-like autoimmunity after infection. First, SARS-CoV-2-infected human angiotensin-converting enzyme 2 (ACE2) transgenic mice exhibited decreased salivation, elevated antinuclear antibodies (ANA), and lymphocytic infiltration in the lacrimal and SG. The sera from patients with COVID-19 sera showed increased ANA (i.e., anti-SSA [Sjögren's-syndrome-related antigen A]/anti-Ro52 and anti-SSB [SS-antigen B]/anti-La). Male patients showed elevated anti-SSA compared with female patients, and female patients exhibited diverse ANA patterns. SG biopsies from convalescent COVID-19 patients were microscopically similar to SjD SG with focal lymphocytic infiltrates in 4 of 6 patients and 2 of 6 patients exhibiting focus scores of at least 2. Lastly, monoclonal antibodies produced in recovered patients blocked ACE2/spike interaction and cross-reacted with nuclear antigens. Our study shows a direct association between SARS-CoV-2 and SjD. Hallmark features of SjD-affected SGs were histologically indistinguishable from convalescent COVID-19 patients. The results implicate that SARS-CoV-2 could be an environmental trigger for SjD.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
JCI insight - 8(2023), 24 vom: 22. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shen, Yiran [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiotensin-Converting Enzyme 2 |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 10.02.2024 published: Electronic UpdateOf: medRxiv. 2022 Oct 21;:. - PMID 36324812 Citation Status MEDLINE |
|---|
| doi: |
10.1172/jci.insight.166540 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361743645 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361743645 | ||
| 003 | DE-627 | ||
| 005 | 20240210232632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1172/jci.insight.166540 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM361743645 | ||
| 035 | |a (NLM)37676726 | ||
| 035 | |a (PII)e166540 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shen, Yiran |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evidence of a Sjögren's disease-like phenotype following COVID-19 in mice and humans |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateOf: medRxiv. 2022 Oct 21;:. - PMID 36324812 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Sjögren's Disease (SjD) is a systemic autoimmune disease characterized by lymphocytic inflammation of the lacrimal and salivary glands (SG), dry eyes and mouth, and systemic symptoms. SARS-CoV-2 may trigger the development or progression of autoimmune diseases. To test this, we used a mouse model of SARS-CoV-2 infection and convalescent patients' blood and SG in order to understand the development of SjD-like autoimmunity after infection. First, SARS-CoV-2-infected human angiotensin-converting enzyme 2 (ACE2) transgenic mice exhibited decreased salivation, elevated antinuclear antibodies (ANA), and lymphocytic infiltration in the lacrimal and SG. The sera from patients with COVID-19 sera showed increased ANA (i.e., anti-SSA [Sjögren's-syndrome-related antigen A]/anti-Ro52 and anti-SSB [SS-antigen B]/anti-La). Male patients showed elevated anti-SSA compared with female patients, and female patients exhibited diverse ANA patterns. SG biopsies from convalescent COVID-19 patients were microscopically similar to SjD SG with focal lymphocytic infiltrates in 4 of 6 patients and 2 of 6 patients exhibiting focus scores of at least 2. Lastly, monoclonal antibodies produced in recovered patients blocked ACE2/spike interaction and cross-reacted with nuclear antigens. Our study shows a direct association between SARS-CoV-2 and SjD. Hallmark features of SjD-affected SGs were histologically indistinguishable from convalescent COVID-19 patients. The results implicate that SARS-CoV-2 could be an environmental trigger for SjD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Autoimmunity | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Rheumatology | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 700 | 1 | |a Voigt, Alexandria |e verfasserin |4 aut | |
| 700 | 1 | |a Goranova, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Abed, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Kleiner, David E |e verfasserin |4 aut | |
| 700 | 1 | |a Maldonado, Jose O |e verfasserin |4 aut | |
| 700 | 1 | |a Beach, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Pelayo, Eileen |e verfasserin |4 aut | |
| 700 | 1 | |a Chiorini, John A |e verfasserin |4 aut | |
| 700 | 1 | |a Craft, William F |e verfasserin |4 aut | |
| 700 | 1 | |a Ostrov, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Ramiya, Vijay |e verfasserin |4 aut | |
| 700 | 1 | |a Sukumaran, Sukesh |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Ashley N |e verfasserin |4 aut | |
| 700 | 1 | |a Hanrahan, Kaley C |e verfasserin |4 aut | |
| 700 | 1 | |a Tuanyok, Apichai |e verfasserin |4 aut | |
| 700 | 1 | |a Warner, Blake M |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Cuong Q |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCI insight |d 2016 |g 8(2023), 24 vom: 22. Dez. |w (DE-627)NLM257703918 |x 2379-3708 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:24 |g day:22 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1172/jci.insight.166540 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 24 |b 22 |c 12 | ||